The pharmacokinetics of pioglitazone in Thai healthy subjects

Journal of the Medical Association of Thailand

Volumn 89, Issue 12, 2006, Pages 2116-2122

  Wittayalertpanya, Supeecha ^a   Chompootaweep, Sumana ^a   Thaworn, Nongnuch ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Pharmacokinetics; Pioglitazone

Indexed keywords

ACETONITRILE; PIOGLITAZONE; ROSIGLITAZONE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LIVER TOXICITY; MALE; NORMAL HUMAN; SINGLE DRUG DOSE; ULTRAVIOLET RADIATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYPOGLYCEMIC AGENTS; MALE; THAILAND; THIAZOLIDINEDIONES;

EID: 33845661911     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Baba S. Pioglitazone: a review of Japanese clinical studies. Curr Med Res Opin 2001; 17: 166-89.
2. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.
3. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63: 1373-405.
4. Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108(Suppl 2): 234-42.
5. ACTOS. Product information for Actos. Available from: http://www.actos.com/pi.pdf. Accessed 20 Dec, 2004.
6. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract 2001; (Suppl): 19-25.
7. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005; 44: 1209-25.
8. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM). Guidance for industry: bioanalytical method validation. May 2001. Available from: http://www.fda.gov/CDER/GUIDANCE/4252fnl.htm Accessed 26 Oct, 2006
9. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005; 77: 404-14.
10. Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005; 61: 831-6.
11. Kiyota Y, Kondo T, Maeshiba Y, Hashimoto A, Yamashita K, Yoshimura Y, et al. Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneimittelforschung 1997; 47: 22-8.